Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Cancer ; 1(11): 1082-1096, 2020 11.
Article in English | MEDLINE | ID: mdl-34085047

ABSTRACT

Understanding the intricacies of lethal prostate cancer poses specific challenges due to difficulties in accurate modeling of metastasis in vivo. Here we show that NPK EYFP mice (for Nkx3.1 CreERT2/+ ; Pten flox/flox ; Kras LSL-G12D/+ ; R26R-CAG-LSL-EYFP/+) develop prostate cancer with a high penetrance of metastasis to bone, thereby enabling detection and tracking of bone metastasis in vivo and ex vivo. Transcriptomic and whole-exome analyses of bone metastasis from these mice revealed distinct molecular profiles conserved between human and mouse and specific patterns of subclonal branching from the primary tumor. Integrating bulk and single-cell transcriptomic data from mouse and human datasets with functional studies in vivo unravels a unique MYC/RAS co-activation signature associated with prostate cancer metastasis. Finally, we identify a gene signature with prognostic value for time to metastasis and predictive of treatment response in human patients undergoing androgen receptor therapy across clinical cohorts, thus uncovering conserved mechanisms of metastasis with potential translational significance.


Subject(s)
Bone Neoplasms , Prostatic Neoplasms , Animals , Bone Neoplasms/genetics , Castration , Gene Expression Regulation, Neoplastic , Humans , Male , Mice , Prostatic Neoplasms/genetics , Transcription Factors/genetics
2.
Dis Model Mech ; 11(11)2018 11 16.
Article in English | MEDLINE | ID: mdl-30266798

ABSTRACT

Although it is known that inflammation plays a critical role in prostate tumorigenesis, the underlying processes are not well understood. Based on analysis of genetically engineered mouse models combined with correlative analysis of expression profiling data from human prostate tumors, we demonstrate a reciprocal relationship between inflammation and the status of the NKX3.1 homeobox gene associated with prostate cancer initiation. We find that cancer initiation in aged Nkx3.1 mutant mice correlates with enrichment of specific immune populations and increased expression of immunoregulatory genes. Furthermore, expression of these immunoregulatory genes is similarly increased in human prostate tumors having low levels of NKX3.1 expression. We further show that induction of prostatitis in Nkx3.1 mutant mice accelerates prostate cancer initiation, which is coincident with aberrant cellular plasticity and differentiation. Correspondingly, human prostate tumors having low levels of NKX3.1 have de-regulated expression of genes associated with these cellular processes. We propose that loss of function of NKX3.1 accelerates inflammation-driven prostate cancer initiation potentially via aberrant cellular plasticity and impairment of cellular differentiation.This article has an associated First Person interview with the first author of the paper.


Subject(s)
Carcinogenesis/pathology , Inflammation/pathology , Prostatic Neoplasms/pathology , Transcription Factors/deficiency , Animals , Cell Differentiation , Cell Lineage , Cell Plasticity , Chronic Disease , Gene Expression Regulation , Gene Expression Regulation, Neoplastic , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Humans , Male , Mice, Inbred C57BL , Mice, Mutant Strains , Phenotype , Prostate/metabolism , Prostate/pathology , Prostatic Neoplasms/genetics , Prostatitis/pathology , Transcription Factors/genetics , Transcription Factors/metabolism
3.
Eur Urol ; 72(4): 499-506, 2017 10.
Article in English | MEDLINE | ID: mdl-28385453

ABSTRACT

BACKGROUND: Although men on active surveillance for prostate cancer (PCa) may benefit from intervention with 5α-reductase inhibitors (5-ARIs), it has not been resolved whether 5-ARIs are effective for delaying disease progression and, if so, whether specific patients are more likely to benefit. OBJECTIVE: To identify molecular features predictive of patient response to 5-ARIs. DESIGN, SETTING, AND PARTICIPANTS: Nkx3.1 mutant mice, a model of early-stage PCa, were treated with the 5-ARI finasteride, and histopathological and molecular analyses were performed. Cross-species computational analyses were used to compare expression profiles for treated mice with those of patients who had received 5-ARIs before prostatectomy. INTERVENTION: Finasteride administered to Nkx3.1 mutant mice. 5-ARI-treated patient specimens obtained retrospectively. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Endpoints in mice included histopathology, immunohistochemistry, and molecular profiling. GraphPad Prism software, R-studio, and Matlab were used for statistical and data analyses. RESULTS AND LIMITATIONS: Finasteride treatment of Nkx3.1 mutant mice resulted in a significant reduction in prostatic intraepithelial neoplasia (PIN), as evident from histopathological and expression profiling analyses. Cross-species computational analysis comparing finasteride-treated mice with two independent 5-ARI-treated patient cohorts showed that reduced NKX3.1 expression is predictive of response to 5-ARI. A limitation of the study is that these retrospective human cohorts have relatively few patients with limited clinical outcome data. Future prospective clinical trials are needed to validate whether stratifying patients on the basis of NKX3.1 expression improves the benefit of 5-ARIs during active surveillance. CONCLUSIONS: This co-clinical study implicates NKX3.1 status as a predictor of response to 5-ARIs, and suggests that molecular features, including NKX3.1 expression, may help to identify PCa patients most likely to benefit from 5-ARIs during active surveillance. PATIENT SUMMARY: The aim of precision cancer prevention is to tailor interventions on the basis of individualized patient characteristics. We propose that patients with low NKX3.1 expression are optimal candidates for intervention with 5α-reductase inhibitors as an adjunct to active surveillance.


Subject(s)
5-alpha Reductase Inhibitors/therapeutic use , Biomarkers, Tumor/genetics , Dutasteride/therapeutic use , Finasteride/therapeutic use , Homeodomain Proteins/genetics , Mutation , Prostatic Intraepithelial Neoplasia/drug therapy , Prostatic Neoplasms/drug therapy , Transcription Factors/genetics , 5-alpha Reductase Inhibitors/adverse effects , Aged , Animals , Biomarkers, Tumor/metabolism , Chemotherapy, Adjuvant , Clinical Decision-Making , DNA Mutational Analysis , Dutasteride/adverse effects , Finasteride/adverse effects , Homeodomain Proteins/metabolism , Humans , Male , Mice, Knockout , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Patient Selection , Precision Medicine , Predictive Value of Tests , Prostatectomy , Prostatic Intraepithelial Neoplasia/enzymology , Prostatic Intraepithelial Neoplasia/genetics , Prostatic Intraepithelial Neoplasia/pathology , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Retrospective Studies , Time Factors , Transcription Factors/metabolism , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...